Stockscreener 앱 받기
3.54
0.57%
0.02
시간 외 거래:
3.56
0.02
+0.56%
전일 마감가:
$3.52
열려 있는:
$3.59
하루 거래량:
4.93M
Relative Volume:
1.95
시가총액:
$582.73M
수익:
$361.51M
순이익/손실:
$102.18M
주가수익비율:
5.9257
EPS:
0.5974
순현금흐름:
$112.21M
1주 성능:
-2.48%
1개월 성능:
+1.14%
6개월 성능:
+8.59%
1년 성능:
+406.58%
1일 변동 폭
$3.49
$3.65
1주일 범위
$3.49
$3.79
52주 변동 폭
$0.6601
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.54 | 582.73M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Ironwood Pharmaceuticals StockAnalyst snapshot and sector review at week’s end - AD HOC NEWS
Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan - Stock Titan
Ironwood Pharmaceuticals Inc (IRWD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ironwood Pharmaceuticals Inc - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Institutional Confidence - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Director Julie Mchugh Sells 21,571 Shares of Ironwood Pharmaceuticals Inc (IRWD) - GuruFocus
Ironwood Pharmaceuticals Inc (IRWD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ironwood Pharmaceuticals Inc (IRWD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting - Stock Titan
Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4 - Stock Titan
Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant - Stock Titan
Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares - Stock Titan
[144] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharmaceuticals (IRWD) Jefferies London Healthcare Conference 2024 Summary - Quartr
Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026 - TradingView
Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash - Stock Titan
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - MSN
Ironwood Pharmaceuticals (IRWD) Tops Healthcare Sector with Stro - GuruFocus
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026? - Yahoo Finance
· SEC Filing - MLQ.ai
IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Chart - ChartMill
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead - TradingView
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price, News, Quote & History - Yahoo Finance
Ironwood Pharmaceuticals Expands Linzess Use and Drives Record Q1 2026 Revenue - asatunews.co.id
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess? - Insider Monkey
Ironwood (IRWD) Q1 2026 Earnings Call Transcript - The Globe and Mail
Earnings Preview: IRWD to Report Financial Results Pre-market on May 07 - Moomoo
Ironwood Pharmaceuticals (IRWD) Proxy filing Summary - Quartr
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2026 - BioSpace
Ironwood Pharmaceuticals to Present at Jefferies Global Healthcare Conference - geneonline.com
Ironwood Pharmaceuticals, Inc. (IRWD) stock price, news, quote and history - Yahoo Finance UK
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - investor.ironwoodpharma.com
Ironwood Pharmaceuticals (IRWD) Gains FDA Approval for Linzess i - GuruFocus
FDA approves Linzess for children ages 2-5 with constipation - Investing.com UK
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation - Seeking Alpha
FDA approves constipation drug LINZESS for kids as young as 2 - Stock Titan
Ironwood Pharmaceuticals (IRWD) Receives Strong Buy Rating Follo - GuruFocus
Ironwood Pharmaceuticals (IRWD) Earns Strong Buy Rating from Qua - GuruFocus
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
11.23%
0.45%
자본화:
|
볼륨(24시간):